Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

DrugPolicy / Regulatory

China NMPA Launches PIONEER Program to Accelerate NAMs Adoption in Drug Development

CompanyDeals

Immunocon, MabGalaxy Forge Full-Chain AI Antibody R&D Network for Bispecific Drug Development

CompanyDeals

Vertex Pharmaceuticals to Acquire Crinetics for $10B, Adding PALSONIFY and Atumelnant to Endocrine Portfolio

CompanyDeals

Hainan Shuangcheng Pharmaceutical Secures $10M US Licensing Deal for SC-C141 R&D Project

CompanyDeals

CStone Pharmaceuticals Partners with Arrotex for Sugemalimab Commercialization Across Australia and New Zealand

CompanyDeals

Serapha Bio Secures $2B+ Base Editing Therapy Deal for AATD with YolTech and Completes $230M Merger

Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets
CompanyDeals

Alphamab Oncology, Nanolek Partner on Armocibart Hemophilia Prophylaxis for Russian and EAEU Markets

CompanyDeals

TrueLab Biopharmaceutical, Bionyra Pharma Forge $985M TL1A Antibody Deal with Dual IBD Candidates

CompanyMedical Device

Shanghai ZJ Bio-Tech Ebola Detection Kit Receives WHO Emergency Use Listing for Bundibugyo Strain

CompanyDeals

cAMPfield Therapeutics Launches with $180M Series A to Advance Prifemilast PDE4 Inhibitor for IBD

CompanyDeals

BriSTAR Immunotech Secures $28M Series C to Advance STAR-T Platform and In Vivo Technology